Search

Your search keyword '"Marco, Moschini"' showing total 154 results
Start Over Author "Marco, Moschini" Publisher ovid technologies (wolters kluwer health)
154 results on '"Marco, Moschini"'

1. MP67-06 OUTCOMES OF PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVASION AT MULTIPARAMETRIC MRI MANAGED WITH RADICAL PROSTATECTOMY. DO ALL PATIENTS REALLY NEED A MULTI-MODAL APPROACH?

Author

Francesco Barletta, Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, Riccardo Campi, Andrea Minervini, Sergio Serni, Alessandro Marquis, Jean-Baptiste Beauval, Arnas Rakauskas, Roderick Van Den Bergh, Timo Soeterik, Mathieu Roumiguiè, Luca Afferi, Junlong Zhuang, Hongqian Guo, Agostino Mattei, Paolo Gontero, Elio Mazzone, Giancarlo Marra, Marco Moschini, Sessa Francesco, Armando Stabile, Vito Cucchiara, Nicola Fossati, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2023
Full Text
View/download PDF

2. LBA03-12 BIOLOGY AND PERFORMANCE OF PRE- AND POST-PEMBROLIZUMAB (PEMBRO) VESICAL IMAGING-REPORTING AND DATA SYSTEM (VI-RADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): FULL DATA ANALYSIS FROM A CLINICAL TRIALS PIPELINE

Author

Andrea Necchi, Giuseppe Basile, Ewan Gibb, Giuseppina Calareso, Tiago Padua, Damiano Patanè, Emanuele Crupi, Chiara Mercinelli, Andrea Del Prete, Patrizia Giannatempo, Marco Moschini, Jeffrey Ross, Alberto Briganti, Francesco Montorsi, Antonella Messina, Francesco De Cobelli, and Giorgio Brembilla

Subjects
Urology
Published
2023
Full Text
View/download PDF

3. PD13-09 CLINICAL VALIDATION OF THE EAU2021 INTERMEDIATE RISK NMIBC DEFINITION AND IMPLICATIONS FOR ADJUVANT TREATMENT: A MULTICENTER YAU UROTHELIAL COLLABORATION

Author

Matteo Rosazza, Francesco Soria, Marco Moschini, Francesco Del Giudice, Renate Pichler, Rodolfo Hurle, Stefano Mancon, Diego M Carrion Monsalve, Wojciech Krajewski, Andrea Mari, Simone Mazzoli, Simone Livoti, Daniele Dutto, Matteo De Bellis, Luciano Ola, Francesca Pisano, Chiara Fiameni, Beatrice Lillaz, and Paolo Gontero

Subjects
Urology
Published
2023
Full Text
View/download PDF

4. MP32-16 FUNCTIONAL OUTCOMES IN FEMALE PATIENTS AFTER TRADITIONAL, ORGAN- AND NERVE-SPARING RADICAL CYSTECTOMY AND URINARY DIVERSION FOR BLADDER CANCER: A SYSTEMATIC REVIEW AND POOLED ANALYSES

Author

Ekaterina Laukhtina, Markus Von Deimling, Benjamin Pradere, Takafumi Yanagisawa, Pawel Rajwa, Tatsushi Kawada, Fahad Quhal, Maximilian Pallauf, Alberto Bianchi, Muhammad Majdoub, Hadi Mostafaei, Reza Sari Motlagh, Keiichiro Mori, Dmitry Enikeev, Margit Fisch, Marco Moschini, David D`Andrea, Francesco Soria, Simone Albisinni, Harun Fajkovic, MICHAEL RINK, Jeremy Yuen-Chun Teoh, Paolo Gontero, and Shahrokh F. Shariat

Subjects
Urology
Published
2023
Full Text
View/download PDF

5. MP40-07 HAS THE INTRODUCTION OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE AND TARGETED BIOPSIES LED TO A RISK OF OVERGRADING OF HIGH RISK PROSTATE CANCER? RESULTS FROM A CONTEMPORARY LARGE MULTI-INSTITUTIONAL SERIES

Author

Gabriele Sorce, Armando Stabile, Giorgio Gandaglia, Vito Cucchiara, Elio Mazzone, Marco Moschini, Nicola Fossati, Paolo Gontero, Andrea Minervini, Sergio Serni, Luca Afferi, Agostino Mattei, Junlong Zhuang, Hongqian Guo, Guillaume Ploussard, Razvan-George Rahota, Massimo Valerio, Arnas Rakauskas, Alessandro Marquis, Roderick van den Bergh, Timo Soeterik, Jean Baptiste Beavaul, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2023
Full Text
View/download PDF

6. PD39-06 INTEGRATING INDEX LESION VOLUME TO BETTER CLASSIFY MEN WITH INDOLENT PROSTATE CANCER AMONG PATIENTS WITH INTERMEDIATE RISK DISEASE. RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES

Author

Armando Stabile, Giorgio Gandaglia, Francesco Pellegrino, Elio Mazzone, Vito Cucchiara, Nicola Fossati, Marco Moschini, Agostino Mattei, Luca Afferi, Sergio Serni, Andrea Minervini, Razvan-George Rahota, Guillaume Ploussard, Massimo Valerio, Jean Baptiste Beavaul, Alessandro Marquis, Arnas Rakauskas, Paolo Gontero, Hongqian Guo, Junlong Zhuang, Roderick Van Den Bergh, Timo Soeterik, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2023
Full Text
View/download PDF

7. PD39-04 MPMRI OF THE PROSTATE IN PATIENTS CARRYING A HIGH CLINICAL RISK OF PROSTATE CANCER DIAGNOSIS: IS THIS IMAGING TEST NECESSARY FOR DIAGNOSTIC PURPOSES IN THIS SUBSET OF PATIENTS?

Author

Armando Stabile, Giorgio Gandaglia, Francesco Pellegrino, Vito Cucchiara, Elio Mazzone, Nicola Fossati, Marco Moschini, Agostino Mattei, Luca Afferi, Sergio Serni, Andrea Minervini, Razvan-George Rahota, Guillaume Ploussard, Massimo Valerio, Jean Baptiste Beavaul, Alessandro Marquis, Arnas Rakauskas, Paolo Gontero, Hongqian Guo, Junlong Zhuang, Roderick Van Den Bergh, Timo Soeterik, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2023
Full Text
View/download PDF

8. PD36-04 UTILITY OF PRE- AND POST-PEMBROLIZUMAB VESICAL IMAGING – REPORTING AND DATA SYSTEM (VIRADS) TO PREDICT THE PATHOLOGICAL RESPONSE IN MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): AN ANALYSIS OF THE PURE-01 COHORT

Author

Giuseppe Basile, Giorgio Brambilla, Marco Bandini, Daniele Raggi, Laura Marandino, Tiago Costa De Padua, Emanuele Crupi, Renzo Colombo, Maurizio Colecchia, Roberta Lucianò, Marco Moschini, Jeffrey S Ross, Alberto Briganti, Francesco Montorsi, Francesco De Cobelli, and Andrea Necchi

Subjects
Urology
Published
2023
Full Text
View/download PDF

10. MP38-03 DOES PROSTATE CANCER FAMILY HISTORY HAVE AN IMPACT ON ACTIVE SURVEILLANCE ADHERENCE IN MEN WITH LOW- OR FAVOURABLE INTERMEDIATE RISK DISEASE?

Author

Riccardo Leni, Armando Stabile, Giorgio Gandaglia, Vito Cucchiara, Marco Bandini, Elio Mazzone, Leonardo Quarta, Paolo Zaurito, Francesco De Cobelli, Giorgio Brembilla, Nicola Fossati, null Lugano, null Switzerland, Emanuele Zaffuto, Marco Moschini, Giulio Avesani, Federico Dehò, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2023
Full Text
View/download PDF

16. Features and management of men with pN1 cM0 prostate cancer after radical prostatectomy and lymphadenectomy: a systematic review of population-based evidence

Author

Christian D. Fankhauser, Claudia Kesch, Igor Tsaur, Veeru Kasivisvanathan, Jonathan Olivier, Felix Preisser, Fabio Zattoni, Guillaume Ploussard, Marco Moschini, Ignacio Puche-Sanz, Isabel Heidegger, Peter Ka-Fung Chiu, Derya Tilki, Alexander Kretschmer, M. Valerio, G. Marra, Francesco Ceci, Charles Laine, Constance Thibault, Roderick C.N. van den Bergh, Benjamin Pradere, and Giorgio Gandaglia

Subjects
Male, Oncology, medicine.medical_specialty, Urology, medicine.medical_treatment, Medizin, population-based studies, positive nodes, Androgen deprivation therapy, Prostate cancer, Quality of life, Internal medicine, Humans, Medicine, Stage (cooking), Lymph node, Adjuvant, Neoplasm Staging, Retrospective Studies, Prostatectomy, Radiotherapy, business.industry, Prostatic Neoplasms, Androgen Antagonists, lymph node, Prostate-Specific Antigen, prostate cancer, medicine.disease, radical prostatectomy, Prostate-specific antigen, medicine.anatomical_structure, Lymph Node Excision, Lymphatic Metastasis, Quality of Life, Radiotherapy, Adjuvant, Lymphadenectomy, Population-based studies, Positive nodes, Radical prostatectomy, business
Abstract

Purpose of review To investigate the features and optimal management of pN+ cM0 prostate cancer (PCa) according to registry-based studies. Recent findings Up to 15% of PCa patients harbor lymph node invasion (pN+) at radical prostatectomy plus lymph node dissection. Nonetheless, the optimal management strategy in this setting is not well characterized. Summary We performed a systematic review including n = 13 studies. Management strategies comprised 13 536 men undergoing observation, 11 149 adjuvant androgen deprivation therapy (aADT), 7,075 adjuvant radiotherapy (aRT) +aADT and 705 aRT. Baseline features showed aggressive PCa in the majority of men. At a median follow-up ranging 48-134months, Cancer-related death was 5% and overall-mortality 16.6%. aADT and aRT alone had no cancer-specific survival or overall survival advantages over observation only and over not performing aRT, respectively. aADT plus aRT yielded a survival benefit compared to observation and aADT, which in one study, were limited to certain intermediate-risk categories. Age, Gleason, Charlson score, positive surgical margins, pathological stage, and positive nodes number, but not prostate specific antigen, were most relevant prognostic factors. Our work further confirmed pN+ PCa is a multifaceted disease and will help future research in defining its optimal management based on different risk categories to maximize survival and patient's quality of life.

Published
2022
Full Text
View/download PDF

17. Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy

Author

Giuseppe Simone, Evanguelos Xylinas, Luca Afferi, Alberto Briganti, Stefania Zamboni, Shahrokh F. Shariat, Agostino Mattei, Andrea Gallina, Claudio Simeone, Ottavio De Cobelli, Armando Stabile, Julianne G. Schultz, Mario Alvarez-Maestro, Ettore Di Trapani, Francesco Montorsi, Renzo Colombo, Giorgio Gandaglia, Chiara Lonati, Marco Moschini, Matteo Soligo, R. Jeffrey Karnes, Alberto Martini, Martini, Alberto, Afferi, Luca, Zamboni, Stefania, Schultz, Julianne G, Lonati, Chiara, Mattei, Agostino, Karnes, R Jeffrey, Soligo, Matteo, Stabile, Armando, Di Trapani, Ettore, De Cobelli, Ottavio, Simone, Giuseppe, Simeone, Claudio, Alvarez-Maestro, Mario, Gandaglia, Giorgio, Gallina, Andrea, Colombo, Renzo, Briganti, Alberto, Montorsi, Francesco, Xylinas, Evanguelo, Shariat, Shahrokh F, and Moschini, Marco

Subjects
Male, medicine.medical_specialty, Time Factors, recurrence, Urology, medicine.medical_treatment, Urinary Bladder, Cystectomy, Risk Assessment, Disease-Free Survival, cystectomy, Risk Factors, Humans, Medicine, Registries, Watchful Waiting, skin and connective tissue diseases, Aged, Neoplasm Staging, Retrospective Studies, Carcinoma, Transitional Cell, Bladder cancer, business.industry, Age Factors, Follow up studies, Middle Aged, medicine.disease, follow-up studies, Urinary Bladder Neoplasms, Female, Neoplasm Recurrence, Local, urinary bladder neoplasms, business, Variant histology, Follow-Up Studies
Abstract

Presently, major guidelines do not provide specific recommendations on oncologic surveillance for patients who harbor variant histology (VH) bladder cancer (BCa) at radical cystectomy. We aimed to create a personalized followup scheme that dynamically weighs other cause mortality (OCM) vs the risk of recurrence for VH BCa, and to compare it with a similar one for pure urothelial carcinoma (pUC).Within a multi-institutional registry, 528 and 1,894 patients with VH BCa and pUC, respectively, were identified. The Weibull regression was used to detect the time points after which the risk of OCM exceeded the risk of recurrence during followup. The risk of OCM over time was stratified based on age and comorbidities, and the risk of recurrence on pathological stage and recurrence site.Individuals with VH had a higher risk of recurrence (recurrence-free survival 30% vs 51% at 10 years, p0.001) and shorter median time to recurrence (88 vs 123 months, p0.01) relative to pUC. Among VH, micropapillary variant conferred the greatest risk of recurrence on the abdomen and lungs, and mixed variants carried the greatest risk of metastasizing to bones and other sites compared to pUC. Overall, surveillance should be continued for a longer time for individuals with VH BCa. Notably, patients younger than 60 years with VH and pT0/Ta/T1/N0 at radical cystectomy should continue oncologic surveillance after 10 years vs 6.5 years for pUC individuals.VH BCa is associated with greater recurrence risk than pUC. A followup scheme that is valid for pUC should not be applied to individuals with VH. Herein, we present a personalized approach for surveillance that may allow an improved shared decision.

Published
2021
Full Text
View/download PDF

18. Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma

Author

Claudio Simeone, Marco Moschini, Chiara Lonati, Philippe E. Spiess, and Andrea Necchi

Subjects
Male, Oncology, Urologic Neoplasms, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Urology, Population, Disease, Malignancy, DNA Mismatch Repair, Germline mutation, Internal medicine, medicine, Humans, education, Carcinoma, Transitional Cell, education.field_of_study, business.industry, nutritional and metabolic diseases, Cancer, medicine.disease, Colorectal Neoplasms, Hereditary Nonpolyposis, digestive system diseases, Lynch syndrome, Urinary Bladder Neoplasms, Upper tract, Female, DNA mismatch repair, business
Abstract

PURPOSE OF REVIEW To provide a comprehensive overview of diagnosis, treatment, and screening for upper tract urothelial carcinoma (UTUC) among Lynch syndrome patients. RECENT FINDINGS Lynch syndrome is an autosomal dominant disorder resulting from the germline mutation in the mismatch repair (MMR) system. The Lynch syndrome predisposes to early onset of a broad spectrum of tumours, among which UTUC represents the third most frequent malignancy. Since up to 10% of UTUC can be attributed to Lynch syndrome, a correct recognition of this disease provides the opportunity for patients and their relatives to be properly treated for UTUC and to be followed up for other Lynch syndrome-related malignancies. SUMMARY UTUC patients less than 65 years, or UTUC patients with personal history of Lynch syndrome-related cancer, or with one first-degree relative (FDR) less than 50 years with Lynch syndrome-related cancer, or two FDRs with Lynch syndrome-related cancer regardless of age should be referred to molecular testing and subsequent DNA sequencing to confirm Lynch syndrome diagnosis. Considering the increased risk of metachronous recurrence, treatments other than radical nephroureterectomy, such as ureteroscopic laser ablation may represent valuable therapeutic strategies. As Lynch syndrome patients exhibit an approximate 14-fold increased risk of developing UTUC compared with general population, expert recommendations are urgently required in order to point out appropriate screening protocols.

Published
2021
Full Text
View/download PDF

21. PD42-06 THE ACCURACY OF VESICAL IMAGING-REPORTING AND DATA SYSTEM (VI-RADS): AN UPDATED COMPREHENSIVE MULTI-INSTITUTIONAL, MULTI-READERS SYSTEMATIC REVIEW AND META-ANALYSIS FROM DIAGNOSTIC EVIDENCE INTO FUTURE CLINICAL RECOMMENDATIONS

Author

Francesco Del Giudice, Rocco Simone Flammia, Martina Pecoraro, Marco Moschini, David D'Andrea, Benjamin I. Chung, Lucia Martina Pisciotti, Alessandro Sciarra, Ettore De Berardinis, and Valeria Panebianco

Subjects
Urology
Published
2022
Full Text
View/download PDF

22. MP40-19 HOW TO IDENTIFY PATIENTS SUITABLE FOR CONSERVATIVE MANAGEMENT OF UPPER TRACT UROTHELIAL CARCINOMA (UTUC) ACCORDING TO TUMOR SIZE: IMPLICATIONS FOR CLINICAL GUIDELINES

Author

Eugenio Ventimiglia, Christian Corsini, Margherita Fantin, Mario de Angelis, Pietro Dioni, Marco Moschini, Daniele Raggi, Maurilio Ponzoni, Umberto Capitanio, Andrea Necchi, Roberta Lucianò, Olivier Traxer, Alberto Briganti, Francesco Montorsi, Luca Villa, and Andrea Salonia

Subjects
Urology
Published
2022
Full Text
View/download PDF

23. MP40-11 RENAL FUNCTION VARIATION AFTER NEPHROURETERECTOMY FOR UPPER URINARY TRACT CARCINOMA: EVALUATION IN A LARGE MULTICENTER COHORT (RADICAL NEPHROURETERECTOMY OUTCOMES (RANEO) RESEARCH CONSORTIUM)

Author

Alessandro Tafuri, Michele Marchioni, Clara Cerrato, Katia Ododrizzi, Andrea Mari, Riccardo Tellini, Alessandro Veccia, Daniele Amparore, Federica Di Cosmo, Umberto Carbonara, Federica Trovato, Michele Castellani, Letizia M.I. Janello, Lorenzo Bianchi, Giacomo Novara, Fabrizio Dal Moro, Riccardo Schiavina, Elisa De Lorenzis, Paolo Parma, Sebastiano Cimino, Ottavio De Cobelli, Francesco Maiorino, Pierluigi Bove, Fabio Crocerossa, Francesco Cantiello, David D’Andrea, Francesco Porpiglia, Pasquale Ditonno, Emanuele Montanari, Francesco Soria, Paolo Gontero, Giovanni Liguori, Carlo Trombetta, Marco Borghesi, Carlo Terrone, Luigi Schips, Francesco Del Giudice, Alessandro Sciarra, Andrea Galosi, Marco Moschini, Matteo Ferro, Shahrokh F. Shariat, Marta Di Nicola, Michele Battaglie, Andrea Minervini, Maria Angela Cerruto, Vincenzo Pagliarulo, and Alessandro Antonelli

Subjects
Urology
Published
2022
Full Text
View/download PDF

24. PD14-08 COMPARATIVE OUTCOMES OF PRIMARY AND RECURRENT HIGH GRADE NON-MUSCLE INVASIVE AND PRIMARY AND PROGRESSIVE MUSCLE-INVASIVE BLADDER CANCER AFTER RADICAL CYSTECTOMY: RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY

Author

Nico Grossmann, Benjamin Pradere, Frederik König, Pawel Rajwa, Fahad Quhal, Hadi Mostafaei, Ekaterina Laukhtina, Keiichiro Mori, Reza Motlagh, Satoshi Katayama, Christian Fankhauser, Agostino Mattei, Marco Moschini, Piotr Chlosta, Bas van Rhijn, Jeremy Teoh, Eva Compérat, Marek Babjuk, Mohammad Abufaraj, Pierre Karakiewicz, and Shahrokh Shariat

Subjects
Urology
Published
2022
Full Text
View/download PDF

26. MP51-07 THE PROGNOSTIC VALUE OF THE NUMBER OF POSITIVE TARGETED CORES IN MEN WITH POSITIVE MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE. RESULTS FROM A LARGE, MULTI-INSTITUTIONAL SERIES

Author

Armando Stabile, Elio Mazzone, Giorgio Gandaglia, Guillaume Ploussard, Razvan-George Rahota, Massimo Valerio, Riccardo Campi, Andrea Mari, Agostino Mattei, Giancarlo Marra, Jean Baptiste Beauval, Mathieu Roumiguiè, Luca Afferi, Marco Moschini, Paolo Gontero, Roderick van den Bergh, Junlong Zhuang, Hongqian Tuo, Nicola Fossati, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

27. MP56-02 NEOADJUVANT PEMBROLIZUMAB MAY RESULT IN LONG-TERM OUTCOME IMPROVEMENT IN BIOMARKER-UNSELECTED PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC): UPDATED RESULTS FROM PURE-01

Author

Luigi Nocera, Marco Moschini, Daniele Raggi, Laura Marandino, Maurizio Colecchia, Roberta Lucianò, Ewan Gibb, Jeffrey Ross, Antonella Messina, Giuseppina Calareso, Andrea Gallina, Federico Dehò, Alberto Briganti, Francesco Montorsi, and Andrea Necchi

Subjects
Urology
Published
2022
Full Text
View/download PDF

29. PD17-04 PROSTATE CANCERS DETECTED AT MULTI-PARAMETRIC MRI TARGETED VERSUS SYSTEMATIC BIOPSIES: ARE THEY EQUAL? RESULTS FROM A LARGE MULTI-INSTITUTIONAL SERIES

Author

Francesco Barletta, Elio Mazzone, Giorgio Gandaglia, Guillaume Ploussard, Razvan-George Rahota, Massimo Valerio, Riccardo Campi, Andrea Mari, Agostino Mattei, Giancarlo Marra, Jean Baptiste Beauval, Mathieu Roumiguiè, Luca Afferi, Marco Moschini, Paolo Gontero, Roderick van den Bergh, Junlong Zhuang, Hongqian Tuo, Armando Stabile, Nicola Fossati, Francesco De Cobelli, Antonio Esposito, Giorgio Brembilla, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

30. MP23-17 PROGNOSTIC AND PREDICTIVE VALUE OF PREOPERATIVE VASCULAR CELL ADHESION MOLECULE-1 PLASMA LEVELS IN UROTHELIAL CARCINOMA OF THE BLADDER TREATED WITH RADICAL CYSTECTOMY

Author

Keiichiro Mori, Victor Schuettfort, Satoshi Katayama, Ekaterina Laukhtina, Benjamin Pradere, Fahad Quhal, Reza Sari Motlagh, Hadi Mostafaei, Pawel Rajwa, Jeremy Teoh, Marco Moschini, David D’Andrea, Mohammad Abufaraj, Shin Egawa, Pierre Karakiewicz, Yair Lotan, Douglas Scherr, Eva Compérat, and Shahrokh Shariat

Subjects
Urology
Published
2022
Full Text
View/download PDF

31. MP23-11 PERIOPERATIVE COMPLICATIONS AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER: AN INTERNATIONAL MULTICENTER COLLABORATION

Author

Chiara Lonati, Luca Afferi, Ettore Di Trapani, Stefania Zamboni, Claudio Simeone, Alberto Briganti, Francesco Montorsi, Giuseppe Simone, Francesco Soria, M. Carmen Mir, Rafael Sanchez-Salas, Mathieu Roumiguié, Alessandro Antonelli, Kees Hendricksen, Agostino Mattei, Christian D. Fankhauser, Roberto Carando, Jeremy Y.C. Teoh, Shahrokh F. Shariat, Simone Albisinni, Rodolfo Hurle, Angelo Peroni, Evanguelos Xylinas, Wojciech Krajewski, Morgan Roupret, and Marco Moschini

Subjects
Urology
Published
2022
Full Text
View/download PDF

32. MP54-16 IMMEDIATE RADICAL CYSTECTOMY VS. BCG IMMUNOTHERAPY FOR T1 HIGH GRADE NON-MUSCLE-INVASIVE BLADDER CANCER: AN INTERNATIONAL MULTICENTRE COLLABORATION

Author

Chiara Lonati, Luca Afferi, Andrea Mari, Andrea Minervini, Wojciech Krajewski, Marco Borghesi, Gerald B. Schulz, Michael Rink, Francesco Montorsi, Alberto Briganti, Alberto Martini, Stefania Zamboni, Claudio Simeone, Francesco Soria, Jeremy Y. C. Teoh, Mathieu Roumiguié, Morgan Roupret, M. Carmen Mir, Alessandro Antonelli, Kees Hendricksen, Roberto Carando, Christian D. Fankhauser, Philipp Baumeister, Agostino Mattei, Shahrokh F. Shariat, and Marco Moschini

Subjects
Urology
Published
2022
Full Text
View/download PDF

33. MP53-20 ADDED VALUE OF MPMRI IN THE STRATIFICATION OF PATIENTS WITH HIGH-RISK PATIENTS PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY: IMPLICATIONS FOR TAILORED MULTI-MODAL STRATEGIES

Author

Giuseppe Cirulli, Elio Mazzone, Giorgio Gandaglia, Razvan-George Rahota, Giancarlo Marra, Massimo Valerio, Riccardo Campi, Andrea Mari, Agostino Mattei, Marco Moschini, Jean Baptiste Beauval, Mathieu Roumiguiè, Luca Afferi, Paolo Gontero, Armando Stabile, Nicola Fossati, Vito Cucchiara, Giuseppe Rosiello, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

35. MP43-19 DROP-OUT RATES FROM ACTIVE SURVEILLANCE FOR DISEASE PROGRESSION REMAIN CONSISTENT AND NOT NEGLIGIBLE OVER TIME. A PLEA FOR LONG-TERM ASSESSMENT BASED ON A LARGE, PROSPECTIVELY COLLECTED ACTIVE SURVEILLANCE COHORT

Author

Luigi Nocera, Riccardo Leni, Armando Stabile, Giorgio Gandaglia, Elio Mazzone, Gabriele Sorce, Francesco Pellegrino, Francesco Barletta, Simone Scuderi, Andrea Gallina, Nicola Fossati, Emanuele Zaffuto, Marco Moschini, Nazareno Suardi, Shahrokh F. Shariat, Francesco Montorsi, and Alberto Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

38. Ureteral and urethral recurrence after radical cystectomy

Author

Roberto Carando, Marco Moschini, David D'Andrea, and Shahrokh F. Shariat

Subjects
Male, medicine.medical_specialty, Urology, Urinary system, medicine.medical_treatment, 030232 urology & nephrology, Cystectomy, urologic and male genital diseases, 03 medical and health sciences, 0302 clinical medicine, Urethra, Prostatic urethra, Urethrectomy, medicine, Humans, Clinical significance, Carcinoma, Transitional Cell, Urethral Neoplasms, Bladder cancer, medicine.diagnostic_test, urogenital system, business.industry, Transurethral biopsy, medicine.disease, female genital diseases and pregnancy complications, medicine.anatomical_structure, Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, Neoplasm Recurrence, Local, Ureter, business
Abstract

Purpose of review The clinical significance of ureteral and urethral recurrence in patients treated with radical cystectomy for bladder cancer is scarce and heterogeneous. The aim of the current review is to summarize the recent literature on incidence, diagnosis and oncologic outcomes of ureteral and urethral recurrences after radical cystectomy. Recent findings Frozen section analysis (FSA) of ureteral margin had a sensitivity and specificity of 69-77 and 83-96%, respectively. Considering the ureteral margin, the reported sensitivity and specificity were 33-93 and 99-100%, respectively. Transurethral biopsy of the prostatic urethra might help in counseling patients' treatment, although its accuracy and prognostic role is highly questionable. In patients treated with radical cystectomy, recurrence of the urethra or ureteral are rare, occurring approximately in 5% of patients. During the follow-up, urinary cytology and cross-sectional imaging improve the early detection of recurrence in asymptomatic patients, although the majority are diagnosed for symptomatic presentation. Their use should be tailored to the patient's risk of ureteral and/or urethral recurrence. Urethrectomy is indicated in case of singular urethral recurrence, whereas no clear data exists regarding the best management of ureteral recurrence, except surgical removal. Summary Intraoperative FSA of ureters and urethra share good specificity but poor sensitivity. Recurrence at urethra and upper tract are rare and discordant data exists regarding survival outcomes. Oncologic surveillance after radical cystectomy with the aim to detect these recurrences should be tailored to the individualized patient's risk.

Published
2020
Full Text
View/download PDF

39. Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer

Author

Arie Carneiro, Aude Fregeville, Nathalie Cathala, Xavier Cathelineau, Rafael Sanchez-Salas, Rafael Tourinho-Barbosa, Armando Stabile, Anna Colomer Gallardo, Petr Macek, Marco Moschini, Oliver Rojas Claros, Annick Mombet, and Fabio Muttin

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Urology, High intensity focused, Ultrasound, 030232 urology & nephrology, Magnetic resonance imaging, Cancer detection, equipment and supplies, medicine.disease, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Biopsy, medicine, In patient, Radiology, business, human activities, Micro ultrasound
Abstract

Purpose:We compared cancer detection rates in patients who underwent magnetic resonance imaging cognitive guided micro-ultrasound biopsy vs robotic ultrasound magnetic resonance imaging fusion biop...

Published
2020
Full Text
View/download PDF

40. Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience

Author

Arie Carneiro, Nathalie Cathala, Rafael Sanchez-Salas, Sylvain Collura-Merlier, Marcos Tobias-Machado, Marco Moschini, Rafael Tourinho-Barbosa, Oliver Rojas Claros, Arnas Bakavicius, Xavier Cathelineau, and Armando Stabile

Subjects
Male, medicine.medical_specialty, Urology, medicine.medical_treatment, 030232 urology & nephrology, Cryotherapy, Cryosurgery, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Prostate, Biopsy, medicine, Humans, Aged, Retrospective Studies, Prostatectomy, medicine.diagnostic_test, business.industry, Ultrasound, Prostatic Neoplasms, Cryoablation, Middle Aged, medicine.disease, humanities, High-intensity focused ultrasound, Treatment Outcome, medicine.anatomical_structure, Cohort, High-Intensity Focused Ultrasound Ablation, Radiology, business
Abstract

We report oncologic outcomes in patients treated with focal therapy for prostate cancer.We retrospectively analyzed a single institution cohort of men with localized prostate cancer who received focal therapy using high intensity focused ultrasound or cryotherapy from 2009 to 2018. Focal therapy was offered for low or intermediate risk disease (prostate specific antigen less than 20 ng/ml, Gleason score 7 or less and clinical stage T2b or less). Patients with previous prostate cancer treatment or less than 6 months of followup were excluded from study. Failure was defined as local or systemic salvage treatment, a positive biopsy Gleason score of 7 or greater in-field or out-of-field in nontreated patients, prostate cancer metastasis or prostate cancer specific death. Cox regression analysis was done to identify independent predictors of failure after focal therapy.Of the 309 patients included in study 190 and 119 were treated with high intensity focused ultrasound and cryotherapy, respectively. Median followup was 45 months. At 1, 3 and 5 years the failure-free survival rate was 95%, 67% and 54%, and the radical treatment-free survival rate was 99%, 79% and 67%, respectively. The 5-year metastasis-free survival rate was 98% and no prostate cancer specific death was registered in this cohort. Before focal therapy a biopsy Gleason score of 7 (3 + 4) or greater (HR 2.4, p0.001) and nadir prostate specific antigen (HR 2.2, p0.001) were independently associated with failed focal therapy. In the salvage focal therapy setting in-field recurrence after primary focal therapy was associated with poorer failure-free survival (p=0.02).Almost half of the men were free of focal therapy failure 5 years after treatment. Still, a significant proportion experienced recurrence at the midterm followup. The preoperative biopsy Gleason score and nadir prostate specific antigen were significantly associated with treatment failure.

Published
2020
Full Text
View/download PDF

41. MP05-16 WHAT IS THE DEFINITION OF MISCLASSIFICATION IN PATIENTS WITH GRADE GROUP 2 PROSTATE CANCER ELIGIBLE FOR ACTIVE SURVEILLANCE AND DIAGNOSED WITH MRI TARGETED BIOPSY? A MULTI-INSTITUTIONAL ANALYSIS WITH PATHOLOGICAL CONFIRMATION

Author

Guillaume Ploussard, Jean Baptiste Beavaul, Alberto Briganti, Giancarlo Marra, Francesco Montorsi, Riccardo Campi, Gontero Paolo, Massimo Valerio, Mathieu Roumiguié, Francesco Barletta, Elio Mazzone, Alessandro Marquis, Giorgio Gandaglia, Simone Scuderi, Hongqian Tuo, Daniele Robesti, Luca Afferi, Razvan-George Rahota, Armando Stabile, Andrea Mari, Marco Moschini, and Riccardo Leni

Subjects
Oncology, Prostate cancer, medicine.medical_specialty, business.industry, Urology, Internal medicine, medicine, In patient, urologic and male genital diseases, medicine.disease, business, Targeted biopsy, Pathological
Abstract

INTRODUCTION AND OBJECTIVE:Although PCa misclassification and progression during active surveillance (AS) have been well defined for men with low risk Prostate Cancer (PCa), the definition of adver...

Published
2021
Full Text
View/download PDF

42. MP45-20 FSHR EXPRESSION ALLOWS ACCURATE DIFFERENTIATION OF BENIGN AND MALIGNANT RENAL NEOPLASMS: A PILOT STUDY

Author

Nicolae Ghinea, Rafael Sanchez-Salas, Giancarlo Marra, Caio Pasquali, Xavier Cathelineau, Paolo Gontero, Marine Lefèvre, Laetitia Lesage, Didier Meseure, Petr Macek, Cristiano Linck Pazeto, Marco Moschini, André Nicolas, and Claudia Filippini

Subjects
endocrine system, Expression (architecture), business.industry, Urology, Cancer research, CD34, Medicine, Renal cancers, business, Renal neoplasm
Abstract

INTRODUCTION AND OBJECTIVE:Our aim was to evaluate the expression of CD34 and FSHR in different renal cancers (RCa) and their ability in differentiating benign from malignant diseases.METHODS:A 10x...

Published
2021
Full Text
View/download PDF

43. MP48-12 ONCOLOGIC SURVEILLANCE FOR SURGICALLY-TREATED HIGH RISK UPPER TRACT UROTHELIAL CARCINOMA

Author

Alberto Martini, Andrea Necchi, Francesco Montorsi, Marco Moschini, Chiara Lonati, Alberto Briganti, Stefania Zamboni, Claudio Simeone, Shahrokh F. Shariat, Agostino Mattei, and Luca Afferi

Subjects
medicine.medical_specialty, Upper tract, business.industry, Urology, medicine, business, Cystoscopies, Urothelial carcinoma
Abstract

INTRODUCTION AND OBJECTIVE:The cornerstone of oncologic surveillance for surgically-treated high risk upper tract urothelial carcinoma (HR UTUC) is represented by cystoscopies and imaging. Guidelin...

Published
2021
Full Text
View/download PDF

44. MP48-08 METASTASIS WITHIN THREE YEARS FROM RADICAL NEPHROURETERECTOMY AS A BRIDGE TO OVERALL SURVIVAL: IMPLICATIONS FOR PATIENT COUNSELING, CURRENT, AND FUTURE STUDIES

Author

Alberto Briganti, Alberto Martini, Luca Afferi, Marco Moschini, Claudio Simeone, Stefania Zamboni, Chiara Lonati, Shahrokh F. Shariat, Agostino Mattei, Andrea Necchi, and Francesco Montorsi

Subjects
medicine.medical_specialty, Future studies, Upper tract, business.industry, Urology, General surgery, medicine, Overall survival, Patient counseling, medicine.disease, business, Metastasis, Urothelial carcinoma
Abstract

INTRODUCTION AND OBJECTIVE:Survival outcomes of patients treated with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) remain unsatisfactory and intermediate clinical en...

Published
2021
Full Text
View/download PDF

45. MP41-02 VARIANT HISTOLOGY AS PREDICTOR OF UPSTAGING AT RADICAL CYSTECTOMY FOR UROTHELIAL BLADDER CANCER

Author

Robert Jeffrey Karnes, Stefania Zamboni, Sarah H.M. Einerhand, Alberto Briganti, Kees Hendricksen, Cédric Poyet, Marco Moschini, Giuseppe Simone, Chiara Lonati, Ottavio De Cobelli, Agostino Mattei, Ettore Di Trapani, Michael Rink, Claudio Simeone, Luca Afferi, Philipp Baumeister, Andrea Necchi, and Francesco Montorsi

Subjects
Cystectomy, medicine.medical_specialty, Bladder cancer, business.industry, Urology, medicine.medical_treatment, medicine, Variant histology, business, medicine.disease
Published
2021
Full Text
View/download PDF

46. MP48-10 THE ROLE OF PRIOR BLADDER CANCER ON ANY RECURRENCE AND DISTANT METASTASIS IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY

Author

Alberto Briganti, Marco Moschini, Chiara Lonati, Stefania Zamboni, Alberto Martini, Shahrokh F. Shariat, Agostino Mattei, Claudio Simeone, Luca Afferi, Andrea Necchi, and Francesco Montorsi

Subjects
Oncology, medicine.medical_specialty, Bladder cancer, business.industry, Urology, Internal medicine, medicine, Distant metastasis, In patient, medicine.disease, business
Abstract

INTRODUCTIONAND OBJECTIVE: Literature lacks clear evidence regarding the association between history of prior UC and survival outcomes in patients treated with radical nephroureterectomy (RNU) for ...

Published
2021
Full Text
View/download PDF

47. MP13-04 LYMPHOVASCULAR INVASION IMPROVES PREDICTION FOR LOCAL RECURRENCE AFTER RADICAL CYSTECTOMY FOR MUSCLE INVASIVE BLADDER CANCER: AN EXTERNAL VALIDATION OF NECCHI ET AL. NOMOGRAM FOR LOCORREGIONAL RECURRENCE AFTER RADICAL CYSTECTOMY

Author

Oscar Buisan Rueda, Marco Moschini, Anna Colomer Gallardo, Rafael Sanchez-Salas, Xavier Cathelineau, Roger Freixa Sala, Joan Areal Calama, Petr Macek, and Yann Barbe

Subjects
medicine.medical_specialty, Bladder cancer, business.industry, Lymphovascular invasion, Urology, medicine.medical_treatment, External validation, Muscle invasive, Nomogram, medicine.disease, Cystectomy, medicine, business
Abstract

INTRODUCTION AND OBJECTIVE:To validate a prognostic nomogram (Necchi et al, nomogram-doi:10.1016/j.clgc.2018.09.008) for exclusive locoregional recurrence after radical cystectomy and bilateral pel...

Published
2021
Full Text
View/download PDF

48. MP48-17 URETERAL STENTING DOES NOT INCREASE THE RISK OF METACHRONOUS UPPER TRACT UROTHELIAL CARCINOMA IN PATIENTS WITH BLADDER CANCER PRESENTING WITH HYDRONEPHROSIS IN COMPARISON WITH PERCUTANEOUS NEPHROSTOMY

Author

Giuseppe Simone, Shahrokh F. Shariat, Mathieu Roumiguié, Evanguelos Xylinas, Morgan Rouprêt, Simone Albisinni, Andrea Mari, Wojciech Krajewski, Agostino Mattei, Stefania Zamboni, Marco Moschini, Gerald Schulz, Maria Carmen Mir, Chiara Lonati, Luca Afferi, Francesco Montorsi, Alberto Briganti, Alessandro Antonelli, Alessandro Tafuri, Maria J. Ribal, Francesco Soria, Mario Alvarez-Maestro, Jeremy Yuen-Chun Teoh, and Peter McL. Black

Subjects
musculoskeletal diseases, medicine.medical_specialty, Bladder cancer, urogenital system, business.industry, Decompression, Urology, medicine.medical_treatment, urologic and male genital diseases, medicine.disease, female genital diseases and pregnancy complications, surgical procedures, operative, Upper tract, Percutaneous nephrostomy, Medicine, In patient, business, Hydronephrosis, Upper urinary tract, Urothelial carcinoma
Abstract

INTRODUCTION AND OBJECTIVE:The decompression of the upper urinary tract (UUT) in patients with ureteral obstruction may be performed through ureteral stenting (US) or percutaneous nephrostomy (PN)....

Published
2021
Full Text
View/download PDF

49. PD63-07 INTRAVESICAL THERAPY IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF ONCOLOGIC OUTCOMES

Author

Dmitry Enikeev, Shahrokh F. Shariat, Abdallah Al-Ani, Francesco Soria, Nico С. Grossmann, Victor M. Schuettfort, Harun Fajkovic, Marco Moschini, Hadi Mostafaei, Mustafa Rami Ali, Fahad Quhal, Reza Sari Motlagh, Keiichiro Mori, Ekaterina Laukhtina, Satoshi Katayama, Mohammad Abufaraj, and Benjamin Pradere

Subjects
Oncology, medicine.medical_specialty, Bladder cancer, business.industry, Urology, Meta-analysis, Internal medicine, Medicine, In patient, Intermediate risk, business, medicine.disease, Non muscle invasive
Abstract

INTRODUCTION AND OBJECTIVE:This systematic review and network meta-analysis (NMA) aimed to summarize the available evidence on the oncologic outcomes of intravesical therapy in patients with interm...

Published
2021
Full Text
View/download PDF

50. MP13-11 COBRA SCORE ADEQUATELY IDENTIFIES HIGHER RISK OF CANCER MORTALITY AND LYMPHOVASCULAR INVASION INFORMATION FURTHER IMPROVES ITS PERFORMANCE

Author

Rafael Sanchez-Salas, Anna Colomer Gallardo, Joan Areal Calama, Petr Macek, Oscar Buisan Rueda, Marco Moschini, Roger Freixa Sala, Yann Barbe, and Xavier Cathelineau

Subjects
Oncology, Cancer mortality, medicine.medical_specialty, Lymphovascular invasion, business.industry, Urology, medicine.medical_treatment, Cancer, Cobra, medicine.disease, humanities, Cystectomy, Internal medicine, medicine, business, computer, computer.programming_language, Urothelial carcinoma
Abstract

INTRODUCTION AND OBJECTIVE:To externally validate the COBRA score (tool predicting cancer-specific survival after radical cystectomy for urothelial carcinoma; Welty et al Cancer 2017, DOI: 10.1002/...

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results